Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo

Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10031-3. doi: 10.1073/pnas.191379498.

Authors

G B Mills¹, Y Lu, E C Kohn

Affiliation

¹ Department of Molecular Therapeutics, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. gmills@mail.mdanderson.org

No abstract available

Publication types

Comment

MeSH terms

Animals
Ataxia Telangiectasia Mutated Proteins
Cell Cycle Proteins / antagonists & inhibitors
Drosophila Proteins*
Enzyme Inhibitors / therapeutic use*
Focal Adhesion Kinase 2
Humans
Mice
Mice, Knockout
Mutation*
Neoplasms, Experimental / drug therapy
Neoplasms, Experimental / genetics
Neoplasms, Experimental / metabolism
PTEN Phosphohydrolase
Phosphoinositide-3 Kinase Inhibitors*
Phosphoric Monoester Hydrolases / genetics*
Protein Serine-Threonine Kinases*
Protein-Tyrosine Kinases / antagonists & inhibitors
Receptor Protein-Tyrosine Kinases / antagonists & inhibitors
Signal Transduction
Sirolimus / analogs & derivatives
Sirolimus / therapeutic use
Tumor Suppressor Proteins*

Substances

Cell Cycle Proteins
Drosophila Proteins
Enzyme Inhibitors
Phosphoinositide-3 Kinase Inhibitors
Tumor Suppressor Proteins
temsirolimus
Atr protein, mouse
Protein-Tyrosine Kinases
Receptor Protein-Tyrosine Kinases
tor protein, Drosophila
Focal Adhesion Kinase 2
ATR protein, human
Ataxia Telangiectasia Mutated Proteins
Protein Serine-Threonine Kinases
Phosphoric Monoester Hydrolases
PTEN Phosphohydrolase
PTEN protein, human
Sirolimus